Citadel Advisors’s RxSight RXST Stock Holding History
Bought
Maintained
Sold
Other funds holding RXST
NSGL
VCM
Citadel Advisors's RXST Position: Q1 2026 in Review
Citadel Advisors increased its RxSight (RXST) stake by 7% in Q1 2026, buying an estimated $605K and bringing the position to 1,118,719 shares worth $6.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3834.
Citadel Advisors first reported a position in RXST in Q2 2022 and has held it in 16 quarters since. The position peaked at $34.2M in Q4 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.
- Citadel Advisors held 1,118,719 shares of RxSight worth $6.89M as of Q1 2026.
- Citadel Advisors bought 72,897 RxSight shares in Q1 2026, an estimated $605K.
- RxSight made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3834 holding.
- Citadel Advisors first reported a position in RxSight in Q2 2022 and has held it in 16 quarters since.
- Citadel Advisors's RxSight position peaked at $34.2M in Q4 2024.
- 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.